This study, sponsored by the Royal Prince Alfred Hospital in Sydney, Australia, investigates the relationship between hypoglycaemia and QT interval abnormalities in patients with Type 2 Diabetes Mellitus (T2DM) treated with sulfonylureas. Given the increasing focus on cardiovascular safety in diabetes treatments, particularly in light of findings from major trials (ACCORD, ADVANCE, VADT), this research addresses a critical area of concern for both clinicians and pharmaceutical companies. The results may influence treatment guidelines and the development of new therapies, potentially impacting market dynamics for diabetes medications, especially sulfonylureas. Companies involved in diabetes care should monitor these findings closely for implications on product safety profiles and market positioning.